Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial (Q59346000)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

main subject

phase III clinical trial

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

Hein Putter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Daniel Rea

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Annette Hasenburg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jean-Michel Vannetzel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Robert Paridaens

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yasuo Hozumi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Dirk G Kieback

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Lina Asmar

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jan Smeets

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Peyman Hadji

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Stephen E Jones

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Cornelis J H van de Velde

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Caroline Seynaeve

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Elysee T M Hille

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Johan W R Nortier

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

John M S Bartlett

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

321-331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

9762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Tamoxifen: the drug that came in from the cold

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

The analysis of multiple endpoints in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Tutorial in biostatistics: competing risks and multi-state models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962312-4

7 January 2021

10.1016/S0140-6736(10)62312-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247627%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference